FDA Finalizes Guidance on CGT Early-Stage Trials

Drug Industry Daily
A A
Because cellular and gene therapy products can have more severe effects than other types of drug products, potentially leading to organ failure, tumors or death, sponsors should include these as primary safety objectives when designing early-phase clinical trials, the FDA says.

To View This Article:

Login

Subscribe To Drug Industry Daily